|
LEUKEMIA, PHILADELPHIA CHROMOSOME-POSITIVE, RESISTANT TO IMATINIB
|
|
0.700 |
CausalMutation
|
CLINVAR |
|
|
|
|
Myeloid Leukemia, Chronic
|
|
0.800 |
GeneticVariation
|
BEFREE |
T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study.
|
16093432 |
2005 |
|
B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1
|
|
0.100 |
GeneticVariation
|
BEFREE |
T315I mutation in Ph-positive acute lymphoblastic leukemia is associated with a highly aggressive disease phenotype: three case reports.
|
22593461 |
2012 |
|
Childhood Leukemia
|
|
0.100 |
GeneticVariation
|
BEFREE |
T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system.
|
29967475 |
2018 |
|
leukemia
|
|
0.100 |
GeneticVariation
|
BEFREE |
T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system.
|
29967475 |
2018 |
|
Myeloid Leukemia, Chronic
|
|
0.800 |
GeneticVariation
|
BEFREE |
A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia.
|
18587017 |
2008 |
|
Myeloid Leukemia, Chronic
|
|
0.800 |
GeneticVariation
|
BEFREE |
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
|
25127392 |
2014 |
|
B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1
|
|
0.100 |
GeneticVariation
|
BEFREE |
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
|
25127392 |
2014 |
|
Myeloid Leukemia, Chronic
|
|
0.800 |
GeneticVariation
|
BEFREE |
A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients.
|
21303525 |
2011 |
|
Blast Phase
|
|
0.070 |
GeneticVariation
|
BEFREE |
Adults with Ph+ chronic phase (CP)-, accelerated phase (AP)- or blast phase (BP)-CML, or ALL and documented BCR-ABL T315I mutation were treated with a 5-day continuous infusion of MK-0457 administered every 14 days at 40 mg/m(2)/h, 32 mg/m(2)/h or 24 mg/m(2)/h.
|
25127392 |
2014 |
|
Myeloid Leukemia, Chronic
|
|
0.800 |
GeneticVariation
|
BEFREE |
AHI1 gene expression levels and BCR-ABL1 T315I mutations in chronic myeloid leukemia patients.
|
22183070 |
2011 |
|
leukemia
|
|
0.100 |
GeneticVariation
|
BEFREE |
Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.
|
21926354 |
2011 |
|
Myeloid Leukemia, Chronic
|
|
0.800 |
GeneticVariation
|
BEFREE |
Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
|
26995693 |
2016 |
|
Myeloid Leukemia, Chronic
|
|
0.800 |
GeneticVariation
|
BEFREE |
Allogeneic transplantation remains an important therapeutic option for CML-CP harboring the T315I mutation, patients who fail 2nd generation TKIs, and for all patients in advanced phase disease.
|
23090888 |
2012 |
|
Myeloid Leukemia, Chronic
|
|
0.800 |
GeneticVariation
|
BEFREE |
Alternative strategies to specifically target T315I-BCR-ABL are needed for the treatment of CML patients harboring such a mutation.
|
29358661 |
2018 |
|
leukemia
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although many imatinib-resistant mutations respond well to second-generation TKIs, the threonine-to-isoleucine mutation at codon 315 of the breakpoint cluster region/v-abl Abelson murine leukemia viral oncogene protein fusion Bcr-Abl (T315I) is insensitive to all currently available TKIs.
|
20564073 |
2010 |
|
Childhood Leukemia
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although many imatinib-resistant mutations respond well to second-generation TKIs, the threonine-to-isoleucine mutation at codon 315 of the breakpoint cluster region/v-abl Abelson murine leukemia viral oncogene protein fusion Bcr-Abl (T315I) is insensitive to all currently available TKIs.
|
20564073 |
2010 |
|
leukemia
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although strategies to overcome resistance-mediated T315I mutation may improve the survival of BCR-ABL-positive leukemia patients, there is little information on cell-based studies.
|
20471447 |
2010 |
|
Childhood Leukemia
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although strategies to overcome resistance-mediated T315I mutation may improve the survival of BCR-ABL-positive leukemia patients, there is little information on cell-based studies.
|
20471447 |
2010 |
|
Myeloid Leukemia, Chronic
|
|
0.800 |
GeneticVariation
|
BEFREE |
Although, we continued to monitor bcr-abl transcripts in 14 CML patients (13 chronic phases and 1 accelerated phase) for up to 12 months, there were no patients who were apparently resistant to imatinib due to the T315I mutation.
|
19343480 |
2009 |
|
Childhood Leukemia
|
|
0.100 |
GeneticVariation
|
BEFREE |
Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells.
|
29321163 |
2018 |
|
leukemia
|
|
0.100 |
GeneticVariation
|
BEFREE |
Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells.
|
29321163 |
2018 |
|
Neoplasms
|
|
0.060 |
GeneticVariation
|
BEFREE |
AP24534 inhibited all tested BCR-ABL mutants in cellular and biochemical assays, suppressed BCR-ABL(T315I)-driven tumor growth in mice, and completely abrogated resistance in cell-based mutagenesis screens.
|
19878872 |
2009 |
|
Myeloid Leukemia, Chronic
|
|
0.800 |
GeneticVariation
|
BEFREE |
ARDAP derivative <b>10</b> inhibited the proliferation of BCR/ABL-expressing KU812 and LAMA84 cells from chronic myeloid leukemia (CML) patients in blast crisis and of hematopoietic cells ectopically expressing the imatinib mesylate (IM)-sensitive KBM5-WT or its IM-resistant KBM5-T315I mutation.
|
28523104 |
2017 |
|
Blast Phase
|
|
0.070 |
GeneticVariation
|
BEFREE |
ARDAP derivative <b>10</b> inhibited the proliferation of BCR/ABL-expressing KU812 and LAMA84 cells from chronic myeloid leukemia (CML) patients in blast crisis and of hematopoietic cells ectopically expressing the imatinib mesylate (IM)-sensitive KBM5-WT or its IM-resistant KBM5-T315I mutation.
|
28523104 |
2017 |